BioCentury | Nov 10, 2020
Finance
Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more
...converted into a pivotal trial.Inmagene adds $21M in series BShanghai-based Inmagene Biopharmaceuticals Co. Ltd. said Vertex Ventures China...
